Qiagen (NYSE:QGEN – Free Report) – Analysts at Zacks Research upped their Q3 2024 earnings per share estimates for shares of Qiagen in a note issued to investors on Monday, September 4th. Zacks Research analyst M. Mondal now anticipates that the company will post earnings per share of $0.56 for the quarter, up from their prior estimate of $0.55. The consensus estimate for Qiagen’s current full-year earnings is $2.07 per share.
Qiagen (NYSE:QGEN – Get Free Report) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.01. Qiagen had a return on equity of 13.72% and a net margin of 17.04%. The firm had revenue of $497.00 million during the quarter, compared to analyst estimates of $492.21 million. During the same quarter in the previous year, the business earned $0.51 EPS. Qiagen’s revenue for the quarter was down 8.6% compared to the same quarter last year.
Qiagen Price Performance
Shares of Qiagen stock opened at $42.10 on Thursday. The company has a quick ratio of 1.96, a current ratio of 2.36 and a debt-to-equity ratio of 0.38. Qiagen has a twelve month low of $40.38 and a twelve month high of $51.18. The business has a 50-day moving average price of $45.12 and a 200 day moving average price of $45.44. The firm has a market cap of $9.60 billion, a PE ratio of 28.64, a P/E/G ratio of 10.42 and a beta of 0.37.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Captrust Financial Advisors boosted its holdings in shares of Qiagen by 23.1% during the 1st quarter. Captrust Financial Advisors now owns 1,232 shares of the company’s stock worth $60,000 after purchasing an additional 231 shares during the last quarter. Assetmark Inc. lifted its holdings in Qiagen by 41.6% in the first quarter. Assetmark Inc. now owns 834 shares of the company’s stock valued at $38,000 after acquiring an additional 245 shares during the last quarter. Pitcairn Co. lifted its holdings in Qiagen by 4.4% in the first quarter. Pitcairn Co. now owns 6,988 shares of the company’s stock valued at $321,000 after acquiring an additional 294 shares during the last quarter. LPL Financial LLC lifted its holdings in Qiagen by 2.7% in the second quarter. LPL Financial LLC now owns 11,517 shares of the company’s stock valued at $519,000 after acquiring an additional 306 shares during the last quarter. Finally, Prudential Financial Inc. lifted its holdings in Qiagen by 4.9% in the first quarter. Prudential Financial Inc. now owns 6,921 shares of the company’s stock valued at $327,000 after acquiring an additional 325 shares during the last quarter. 57.99% of the stock is currently owned by institutional investors and hedge funds.
Qiagen Company Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Read More
- Five stocks we like better than Qiagen
- What Are MATANA Stocks?
- These 3 Wood Stocks are about to go on Discount
- What Are Defense Contractor Stocks? How to Invest in Defense
- Same Coin, Different Sides: 2 Observability Stocks Reverse Ways
- Your Comprehensive Guide to Investing in Bank Stocks
- 3 Stocks Awaiting Winter Winds of Opportunity
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
